

R^4 is hydrogen or $-\text{OC}_{1-3}\text{alkyl}$;

R^5 is hydrogen or fluoro; and

n is 1 or 2;

provided that

when R^3 is $-\text{OC}_{1-3}\text{alkyl}$ and R^2 , R^4 , and R^5 are each hydrogen, R^9 is not phenyl;

when R^5 is fluoro, n is 1, and R^2 , R^3 , and R^4 are each hydrogen, R^9 is not phenyl; and


when R^5 is fluoro, R^3 is methyl, and R^2 and R^4 are each hydrogen, R^1 is not $-\text{C}(\text{O})\text{OR}^8$;

or a pharmaceutically-acceptable salt or stereoisomer thereof.


2. The compound of Claim 1, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein:

R^1 is selected from:


(a) $\text{C}_{1-4}\text{alkyl}$, wherein $\text{C}_{1-4}\text{alkyl}$ is optionally substituted with one, two, or three fluoro or with a substituent selected from $-\text{CN}$; $-\text{OC}_{1-3}\text{alkyl}$; phenyl, wherein phenyl is optionally substituted with $-\text{OH}$; pyridinyl, wherein pyridinyl is optionally substituted with $-\text{CN}$;

tetrahydropyranyl; $-\text{C}(\text{O})\text{NHCH}_3$; and  ;

(b) a group selected from




(c) $-\text{C}(\text{O})\text{R}^6$, wherein R^6 is selected from $\text{C}_{1-4}\text{alkyl}$, wherein $\text{C}_{1-4}\text{alkyl}$ is optionally substituted with one, two, or three fluoro or with a substituent selected from $-\text{OH}$ and phenyl;

$\text{C}_{3-6}\text{cycloalkyl}$, wherein $\text{C}_{3-6}\text{cycloalkyl}$ is optionally substituted with $\text{C}_{1-3}\text{alkyl}$; and  , wherein R^7 is $-\text{CN}$ or $-\text{CF}_3$;

(d) $-\text{C}(\text{O})\text{OR}^8$, wherein R^8 is selected from $\text{C}_{1-4}\text{alkyl}$, wherein $\text{C}_{1-4}\text{alkyl}$ is optionally substituted with $-\text{CN}$, $\text{C}_{3-6}\text{cycloalkyl}$, tetrahydrofuranyl, or $-\text{OR}^m$, wherein R^m is hydrogen or $\text{C}_{1-3}\text{alkyl}$; and $\text{C}_{1-4}\text{alkenyl}$; and

(e) $-\text{S}(\text{O})_2\text{R}^9$, wherein R^9 is selected from $\text{C}_{1-4}\text{alkyl}$, wherein $\text{C}_{1-4}\text{alkyl}$ is optionally substituted with $-\text{CN}$, $-\text{OC}_{1-3}\text{alkyl}$, phenyl, pyridinyl, or $\text{C}_{3-6}\text{cycloalkyl}$; $\text{C}_{1-4}\text{alkenyl}$;

C₃₋₆cycloalkyl, wherein C₃₋₆cycloalkyl is optionally substituted with C₁₋₃alkyl; pyridinyl, wherein pyridinyl is optionally substituted with fluoro; heterocycle containing 4 or 5 ring atoms including one nitrogen atom, wherein the heterocycle is bonded to sulfur through the nitrogen atom and the heterocycle is optionally substituted with -CN or -CH₂OCH₃; and



R² is selected from hydrogen, -OCH₃, and -CH₂-R¹⁰, wherein R¹⁰ is selected from -OH, morpholinyl, piperidinyl, wherein piperidinyl is substituted with two fluoro at the 4-position, and piperazinyl, wherein piperazinyl is substituted with methyl at the 4-position;

R³ is selected from hydrogen, -CH₃, -OCH₃, and -C(O)OCH₃;


R⁴ is hydrogen or -OCH₃;

R⁵ is hydrogen or fluoro; and


n is 1 or 2,

provided that when R⁵ is fluoro, R³ is hydrogen.

3. The compound of Claim 2, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein R¹ is C₁₋₄alkyl, wherein C₁₋₄alkyl is optionally substituted with one, two, or three fluoro or with a substituent selected from -CN; -OC₁₋₃alkyl; phenyl, wherein phenyl is optionally substituted with -OH; pyridinyl, wherein pyridinyl is optionally substituted with -CN; tetrahydropyranyl, -C(O)NHCH₃,




4. The compound of Claim 2, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein R¹ is -C(O)R⁶, wherein R⁶ is selected from C₁₋₄alkyl, wherein C₁₋₄alkyl is optionally substituted with one, two, or three fluoro or with a substituent selected from -OH, and phenyl; C₃₋₆cycloalkyl, wherein C₃₋₆cycloalkyl is optionally substituted with



C₁₋₃alkyl; and , wherein R⁷ is -CN or -CF₃.

5. The compound of Claim 2, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein R¹ is -S(O)₂R⁹, wherein R⁹ is selected from C₁₋₄alkyl, wherein C₁₋₄alkyl is optionally substituted with -CN, -OC₁₋₃alkyl, phenyl, pyridinyl, or C₃₋₆cycloalkyl; C₁₋₄alkenyl; C₃₋₆cycloalkyl, wherein C₃₋₆cycloalkyl is

optionally substituted with C₁₋₃alkyl; pyridinyl, wherein pyridinyl is optionally substituted with fluoro; heterocycle containing 4 or 5 ring atoms including one nitrogen atom, wherein the heterocycle is bonded to sulfur through the nitrogen atom and the heterocycle is

optionally substituted with -CN or with -CH₂OCH₃; and .

6. The compound of Claim 2, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein R¹ is selected from:

(a) C₁₋₄alkyl, wherein C₁₋₄alkyl is substituted with one, two, or three fluoro, or with -CN or -C(O)NHCH₃;

(c) -C(O)R⁶, wherein R⁶ is C₁₋₄alkyl, wherein C₁₋₄alkyl is substituted with one, two, or three fluoro; and

(e) -S(O)₂R⁹, wherein R⁹ is pyridinyl; and

R², R³, R⁴, and R⁵ are each hydrogen.

7. The compound of Claim 6, or a pharmaceutically-acceptable salt or stereoisomer thereof, wherein R¹ is selected from -(CH₂)₂CN, -CH₂CH₂F, -CH₂C(O)NHCH₃, -C(O)CHF₂, and -S(O)₂-pyridin-3-yl.

8. The compound of Claim 2 wherein the compound is selected from:

3-((1*R*,3*s*,5*S*)-3-((7-((5-methyl-1*H*-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile,

*N*⁵-((1*R*,3*s*,5*S*)-8-(2-fluoroethyl)-8-azabicyclo[3.2.1]octan-3-yl)-*N*⁷-(5-methyl-1*H*-pyrazol-3-yl)-1,6-naphthyridine-5,7-diamine,

*N*⁷-(5-methyl-1*H*-pyrazol-3-yl)-*N*⁵-((1*R*,3*s*,5*S*)-8-(pyridin-3-ylsulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-1,6-naphthyridine-5,7-diamine,

2-(dimethylamino)-1-((1*R*,3*s*,5*S*)-3-((7-((5-methyl-1*H*-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-9-azabicyclo[3.3.1]nonan-9-yl)ethan-1-one,

2,2-difluoro-1-((1*R*,3*s*,5*S*)-3-((7-((5-methyl-1*H*-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)ethan-1-one,

*N*⁵-((1*R*,3*s*,5*S*)-8-((2-methoxyethyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-*N*⁷-(5-methyl-1*H*-pyrazol-3-yl)-1,6-naphthyridine-5,7-diamine,